Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘JPM19’

Cancer cells Source: Dr. Cecil Fox, NCI

As part of our ongoing mini-series on small emerging companies to watch out for, we have two quite different biotechs focusing on different aspects of immunotherapy on deck today.

We look at what we know, what we recently learned and where things are likely headed in the near to medium term future.

As always, there’s good and bad news along the way, so what are the pitfalls and what’s to be cheerful or encouraged about?

To learn more and get a heads up on our latest immunotherapy coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

While much of the attention and news flow seems to be on the big companies at the JP Morgan Healthcare conference, I also wanted to take time to explore some early oncology developments coming out of small biotech companies.

Next Gen TKIs pointing the way?

TKIs are very much still alive and kicking in many pipelines and no, not everything is all about immuno-oncology, checkpoint blockade or CAR T cell therapies.

We still have to tackle the three horsemen of apocalyse, namely MYC, RAS and TP53, and find ways of making the undruggable finally druggable if we want to succeed in tumours where these driver mutations confer unrelenting oncogenic addiction.

With that in mind, here’s an interview with Dr Charles Baum of Mirati Therapeutics and what they are doing to address some of these challenging issues…

To learn more and get a heads up on our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Unlike last year, rain in San Francisco wasn’t a feature in 2019

If there’s anyone who hasn’t got fed up looking for somewhere to sit and chat or have a meeting in San Francisco at the 2019 JP Morgan Healthcare conference this week, then don’t be surprised…

With meeting space continually at a premium and many attendees unwilling to pay exhorbitant table rental prices, you now see people resorting to the lobby steps at the Sir Francis Drake, while the ladies have the advantage over the gents of access to the powder room in the Westin (with plugs!)

There’s also a movement from the chic to the shabby:

JPM is as much about informal meetings, pitches and confabs about new ideas, as it is about the actual CEO presentations, and so this situation is likely to continue in future years.

Meanwhile, we continue to dive in with our latest daily blog and put a bunch of companies through their paces.  If day 1 is all about the big pharmas, by day 3 the focus is much more on up and coming or mid sized biotechs…

To learn more and get a heads up on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

San Francisco

While much of the focus has been on the mergers and acquisitions at this year’s JP Morgan Healthcare conference, seeing what a few companies have up their sleeves is also intriguing.

In today’s round up we address reader Q&A as well as highlight some presentations and announcements of interest in the cancer research space.

2019 is going to turn out to be a rather critical year for some companies…

If you missed the first day’s highlights and lowlights – check them out here!

To learn more and get a heads up on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Karl the Fog lifts in San Francisco

The annual JP Morgan Healthcare conference in San Francisco is upon us with a bunch of deals, acquisitions and mergers already announced ahead of the meeting with more today now the event has opened.

Some years this meeting sets the scene for a scintillating 12 months ahead for Pharmaland, other years it’s a damp squib highlighted by the fog and rain.

What will 2019 turn out to be? It’s too early to tell but there’s certainly some intriguing elements worthy of initial discussion and review.

To learn more and get a heads up on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!